Scope of the Study
Viral infections commonly affect the upper or lower respiratory tract and are a leading cause of disease and mortality. These viruses are the most frequently implicated causes of asthma attacks. These viral infections can be associated with a wide range of clinical manifestations ranging from self-limited upper respiratory tract infections to more devastating conditions, such as pneumonia. Antiviral drugs are used for respiratory virus infection treatment.
The market study is being classified by Type (Penicillin VK, Amoxicillin, Penicillin G benzathine, Cefadroxil, Erythromycin, Amoxicillin and clavulanate and Others) and major geographies with country level break-up.
AstraZeneca plc (United Kingdom), AbbVie Inc. (United States), Ablynx NV (Belgium), ADMA Biologics (United States), Alnylam Pharmaceuticals, Inc. (United States), Ark Biosciences (China), ImmunoVaccine Technologies (Canada), Aviragen Therapeutics (United States), Boehringer Ingelheim (Germany) and Bavarian Nordic (Denmark) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Gilead Sciences, Inc. (United States), Johnson & Johnson (United States), Kyowa Hakko Kirin Co., Ltd. (Japan), Mymetics Corporation (Switzerland), GlaxoSmithKline plc. (United Kingdom), Teva Pharmaceutical (Israel) and Vaxart, Inc. (United States).
Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Respiratory Virus Infection Drugs market throughout the predicted period.
AdvanceMarketAnalytics has segmented the market of Global Respiratory Virus Infection Drugs market by Type, Application and Region.
On the basis of geography, the market of Respiratory Virus Infection Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
- Increased Prevalence of Diseases such as COVID-19
- Increased Number of Diagnostics Centres and Hospitals
- Rise in the Government Funding for Research and Development
- Increasing Awareness among People about Preventive Healthcare
- Growing Demand from Online Customers
- Increased Resistance of the Viruses to Drugs
- Growth in the Healthcare Industry
- Increased Research and Development Activities
- Rise in the Online Pharmacies
- Stringent Government Rules and Regulations
Market Leaders and their expansionary development strategies
Recently, ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures and commercializes specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases, announced that its acquisition of the assets of Biotest Pharmaceuticals Corporationís Therapy Business Unit (BTBU) has been completed.
Key Target AudienceRespiratory Virus Infection Drugs Manufacturers, Raw Material Suppliers, Distributors, Emerging Companies and End-users
Customization in the Report Available:The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase